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Familial Mediterranean fever (FMF) is a disease of early
onset which can lead to signiﬁcant morbidity. In 2012,
Single Hub and Access point for pediatric Rheumatology
in Europe (SHARE) was launched with the aim of
optimising and disseminating diagnostic and
management regimens for children and young adults
with rheumatic diseases. The objective was to establish
recommendations for FMF focusing on provision of
diagnostic tools for inexperienced clinicians particularly
regarding interpretation of MEFV mutations. Evidence-
based recommendations were developed using the
European League against Rheumatism standard
operating procedure. An expert committee of paediatric
rheumatologists deﬁned search terms for the systematic
literature review. Two independent experts scored articles
for validity and level of evidence. Recommendations
derived from the literature were evaluated by an online
survey and statements with less than 80% agreement
were reformulated. Subsequently, all recommendations
were discussed at a consensus meeting using the
nominal group technique and were accepted if more
than 80% agreement was reached. The literature search
yielded 3386 articles, of which 25 were considered
relevant and scored for validity and level of evidence. In
total, 17 articles were scored valid and used to
formulate the recommendations. Eight recommendations
were accepted with 100% agreement after the
consensus meeting. Topics covered were clinical versus
genetic diagnosis of FMF, genotype–phenotype
correlation, genotype–age at onset correlation, silent
carriers and risk of amyloid A (AA) amyloidosis, and role
of the specialist in FMF diagnosis. The SHARE initiative
provides recommendations for diagnosing FMF aimed at
facilitating improved and uniform care throughout
Europe.
INTRODUCTION
Familial Mediterranean fever (FMF) is the most
common monogenic autoinﬂammatory disease
(AID) mainly affecting the populations originating
from Mediterranean basin.1 2 It is the only AID
with high prevalence in speciﬁc ethnicities, includ-
ing Turks, Arabs, non-Ashkenazi Jews and
Armenians.3 FMF is characterised by recurrent
attacks of fever associated with serositis. Its main
long-term complication is amyloid A (AA) amyloid-
osis, a severe manifestation with poor prognosis.
Colchicine remains the therapeutic choice to
prevent both FMF attacks and complications,4 but
before committing to daily, lifelong treatment, it is
crucial to establish a correct diagnosis. Until
recently, FMF was diagnosed in paediatric patients
using clinical criteria created for adults. Delay in
the appearance of the complete clinical picture in
very young children,5 presence of atypical signs,
absence of a suggestive family history and uncer-
tainty of the family provenance may cause add-
itional diagnostic difﬁculties in this age group.
Mutations in the MEFV gene, on chromosome
16 (16p13.3), encoding a protein named marenos-
trin or pyrin6 7 were found to underlie FMF in
1997 and the majority of patients demonstrate a
Mendelian autosomal recessive pattern of inherit-
ance.6–8 Over time, the number of mutations recog-
nised as related to FMF has increased.9 At ﬁrst, it
was believed that genetic testing would enable phy-
sicians to completely resolve the diagnostic difﬁcul-
ties associated with FMF and so to prevent its
complications. However, over time, it has become
clear that diagnostic interpretation can be very
complex as some FMF patients may display no or
only one of the known MEFV mutations,10 and
conversely that the carriage of MEFV variants is
not always accompanied by clinical symptoms.
In 2012, a European initiative called Single Hub
and Access point for pediatric Rheumatology in
Europe (SHARE) was launched to optimise man-
agement regimens in Europe for children and
young adults with rheumatic diseases. For FMF, the
aim was to provide a diagnostic tool for inexperi-
enced physicians to optimally manage FMF in their
clinical practice and facilitate interpretation of the
diagnostic value of MEFV gene mutations in pre-
dicting FMF phenotype.
METHODS
The development of consensus recommendations
for FMF was based on published data extrapolated
by a systematic literature review and focused on
ﬁve main topics:
▸ Clinical versus genetic diagnosis of FMF
▸ Genotype–phenotype correlation
▸ Genotype–age at onset correlation
▸ Silent carriers and risk for amyloidosis
▸ Role of the specialist in FMF diagnosis.
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Systematic review
A literature search was performed in the PubMed, Embase and
Cochrane databases in June 2013 following the European
League against Rheumatism (EULAR) recommendations for
developing best practices.11 Search terms for titles, abstracts and
MeSh/EmTree terms included ‘Familial Mediterranean Fever’,
‘periodic fever syndrome/s’, ‘autoinﬂammatory disease/s’ and
synonyms. A manual search of all references in the included
articles was performed and reviews were checked for missing
articles. Figure 1 summarises the search algorithm. The search
was limited to English language papers published after 1970.
Screening and selection of papers
Two authors (NMTH and SO) excluded duplicate articles and
selected papers according to predeﬁned criteria (ﬁgure 1),
including those reporting at least 10 FMF patients and discussed
possible discrepancies. When the same patients were described
in more than one paper, only the new, relevant information was
Search Strategy (Pubmed search shown): “Hereditary Autoinflammatory Diseases” [MeSH Terms]
OR “autoinflammatory diseases” [title/abstract] OR “autoinflammatory syndromes” [title/abstract] OR
“periodic fever syndromes” [title/abstract] OR “autoinflammatory disease” [title/abstract] OR
“autoinflammatory syndrome”[title/abstract] OR “periodic fever syndrome” [title/abstract] OR “familial















Embase 2810 Cochrane 7
Removing duplicates
Papers 3386
















Validity assessment with exclusion of studies with poor validity: 8
Figure 1 Flowchart of the strategy for search and selection of articles. The total number of papers per category is higher than the total number of
papers selected for validity assessment because one paper could be selected for more than one category.
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included. If non-validated clinical criteria were proposed, the
paper was excluded as well.
Validity assessment
A core group of six FMF experts (SO, YU, VH, TK, KB and
HO) from different countries evaluated the selected papers
using predeﬁned scoring forms. The forms included both the
data required and methodological quality of the papers. The val-
idity of the studies, all diagnostic, was assessed according to
Whiting et al.12 Each paper was scored by two experts inde-
pendently and discrepancies were discussed between them in
order to reach a consensus. The level of evidence was assessed
according to guidelines for diagnostic procedures furnished by
Zhang et al13 (table 1).
Recommendations
Data from the included papers were extrapolated by one author
(GG) to formulate statements related to the initial questions and
submitted to two FMF experts (SO and YU), appointed as supervi-
sors of the entire process. The resulting statements were resubmit-
ted to a larger group of 21 AID experts of the SHARE project,
including the core group of six FMF experts. Experts completed a
web-based survey in which they agreed or disagreed with each
statement, commenting and reformulating it where necessary.
Statements with agreement lower than 80% were considered pri-
orities for further discussion; those with ≥80% agreement were
considered preliminarily approved, pending ratiﬁcation of the ﬁnal
sentence structure at the consensus meeting.
Consensus
Fourteen experts discussed the recommendations in a consensus
meeting in Genova (Italy) on 18 March 2014 using nominal
group technique (NGT). NGT is a structured face-to-face
meeting designed to encourage equal participation from group
members and to result in a set of prioritised solutions or recom-
mendations.14 A moderator (BF) mediated the discussion of
each statement according to NGT procedures. For each state-
ment, participants spent approximately 20 min sharing com-
ments and thoughts, explaining disagreement if present, and
ﬁnally suggesting the ofﬁcial statement of the recommendation.
Comments were registered in real time. Each statement was
voted on at the beginning, in its original structure, and consid-
ered approved when at least 12 of 14 experts agreed (86%). If
not, the statement was reformulated and voted on again at the
end of the discussion. If agreement was not reached after discus-
sion, the statement was discarded. The strength of each recom-
mendation was graded according to EULAR standardised
operating procedures (table 2).11
RESULTS
Among 3386 papers on FMF found in the literature search, 240
were considered relevant and selected for full text screening
(ﬁgure 1), with 25 deemed suitable for validity assessment. Of
these 25 papers, 17 were judged valid15–31 by the three pairs of
FMF experts and used for the derivation of the recommenda-
tions (ﬁgure 1). Nine diagnostic recommendations were sug-
gested in the online survey and eight were accepted with 100%
agreement after the consensus meeting.
Clinical versus genetic diagnosis of FMF
In general, the diagnosis of FMF is clinical and despite molecu-
lar advances and attempts to validate speciﬁc clinical criteria,
there are still patients for whom deﬁnitive diagnosis or exclusion
of FMF remains deeply problematic.
The Tel Hashomer Hospital created the ﬁrst criteria for FMF
based on observations in the adult Israeli population.32 33 In
1997, new criteria were validated by Livneh et al34 to corrobor-
ate some clinical elements included in the Tel Hashomer criteria
but excluding other manifestations like amyloidosis, which are
less common at onset. Two versions, one more conservative and
extensive than the other, were created, both with a sensitivity
and speciﬁcity above 95%. The evidence that some criteria were
of little or no relevance to children with FMF and the differ-
ences in some clinical manifestations in younger ages (shorter
attacks, not always unilateral chest pain, isolated or missing
fever in some patients) prompted the Turkish group to formu-
late new FMF criteria for the paediatric population in 2009 (the
Turkish FMF Pediatric criteria).35 However, the validation of
these criteria in other ethnic groups and/or in more genetically
heterogeneous populations is still limited (ﬁgure 2).36 Although
clinical criteria represent an invaluable tool for FMF diagnosis,
they are ultimately restricted to clinical experience and therefore
are somewhat open to interpretation by inexperienced physi-
cians who are not familiar with FMF, even in regions with high
prevalence, increasingly favouring genetic conﬁrmation to
support a clinical diagnosis. This raises many questions about
the role of MEFV mutation screening and the interpretation of
speciﬁc sequence variants in FMF diagnosis.
Among the six papers selected for this topic,15 16 26 29–31 one
retrospective cohort study tried to analyse the relationship
between clinical ﬁndings and the most common mutated alleles
of MEFV gene in a paediatric population of 408 patients.15
Among them, 39 patients without detected MEFV mutations
met the Tel Hashomer criteria, while 44 carried mutations, but
did not meet the clinical criteria. Moreover, FMF phenotype in
some patients with one mutant MEFV allele was as severe as
those in patients with two mutated alleles. The authors con-
cluded that MEFV sequence analysis for the diagnosis of FMF
should be performed only in selected patients in order to avoid
possible overdiagnosis.15 Furthermore, if there is no genetic
conﬁrmation, but the phenotype is consistent with FMF, the
physician should not exclude the diagnosis.15 31 Padeh et al26
supported this evidence through the study of 216 Israeli patients
who met clinical FMF diagnostic criteria; only in a third of the
cases was a mutation found. Based on this observation, the
Table 1 Level of evidence for diagnostic procedures
1A Meta-analysis of cohort studies
1B Meta-analysis of case-control studies
2A Cohort studies
2B Case-control studies
3 Non-comparative descriptive studies
4 Expert opinion
Table 2 Strength of recommendations
A Category I evidence
B Category II evidence or extrapolated recommendations from category I
evidence
C Category III evidence or extrapolated recommendations from category I or II
evidence
D Category IV evidence or extrapolated recommendations from category II or III
evidence
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authors recommended the use of genetic testing only in atypical
cases when there are doubts about the clinical diagnosis.
Low sensitivity and speciﬁcity still limit the diagnostic utility
of clinical criteria as demonstrated by other authors who advo-
cate broader indications for genetic testing.16 29 30 Nevertheless,
descriptions of patients with a deﬁnite FMF phenotype not
associated with known MEFV mutations led the same authors to
conclude that new mutations could be present and that the indi-
cation to perform genetic analysis remains clinical.16
During the consensus meeting, the experts conﬁrmed what was
reported in the literature and concluded that FMF is a clinical
diagnosis, which can be supported but not necessarily excluded by
genetic testing (Strength B). A consensus for the identiﬁcation of
evidence-based criteria for the diagnosis of FMF on the basis of
the combination of clinical and genetic features is needed.
Genotype–phenotype correlation
There are about 300 known sequence variants of MEFV, but
only 14 occur commonly in FMF (E148Q, E167D, T267I,
P369S, F479L, I591T, M680I, I692del, M694I, M694V,
K695R, V726A, A744S, R761H), 80% are in exon 10 and the
others in exons 2, 3 and 5.9 We explored the relationship
between FMF phenotypes and the reported MEFV variants and
extrapolated, through the selected papers,15–26 recommenda-
tions regarding M694V, M694I and M680I in exon 10, and
E148Q in exon 2. Data regarding other mutations were too
limited to be used to formulate consensus statements. As well, a
huge variability was found among the selected papers about the
genetic screening methods used to detect mutations, so at
present no conclusive statements could be extrapolated on this
topic (see online supplementary table S1).
Sequence variants in exon 10
M694V is the most frequently encountered mutation in FMF
patients and a number of cohort studies and non-comparative
descriptive studies have shown that homozygosity for M694V is
related to a severe FMF phenotype.15 19 24–26 The retrospective
cohort study by Ozturk et al15 correlated genetic and clinical
criteria by using the severity score created by Pras et al.37 Both
patients homozygous and compound heterozygous for M694V
were found at increased risk for severe disease compared with
one-mutant allele patients and patients not displaying M694V
mutations.15 Mattit and colleagues conﬁrmed these ﬁndings in
83 Syrian patients compared with 242 healthy controls, and
observed that patients with amyloidosis were all M694V/
M694V or M694V/M680I.19 In 2007, Giaglis and coworkers
showed in a Greek population of 152 patients and 140 healthy
controls that homozygotes for M694V present with a more
severe phenotype than compound heterozygotes.20 The litera-
ture therefore provides evidence of the pathogenic role of
M694V as a risk factor for FMF patients developing
disease-related complications and concludes that a patient
homozygous for M694V should always be considered at higher
risk of developing, with very high probability, a severe pheno-
type (Strength B).
The pathogenic role of M694V has also been studied in rela-
tion to the number of mutated alleles. Giaglis et al showed that
FMF patients carrying two mutated alleles (homozygotes or
compound heterozygotes) displayed a more severe phenotype
Figure 2 Sets of clinical criteria for familial Mediterranean fever: Tel Hashomer criteria, Livneh criteria, and Turkish Pediatric criteria.
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than heterozygotes. This is evident in patients homozygous for
M694V, but also true for mutations in positions 680–694 on
exon 10.20 This evidence was supported by Grateau et al in a
population of 303 suspected FMF patients, where, according to
the Tel Hashomer criteria, among 127 patients with deﬁnite
FMF, 85 presented with two mutations, although not speciﬁed
per exon, compared with only 22 of 137 patients with unlikely
FMF.16
In conclusion, FMF patients carrying two common mutated
alleles (homozygotes or compound heterozygotes), especially
the M694V mutation, or mutations in position 680 to 694 on
exon 10, must be considered at-risk of having a more severe
disease (Strength B).
Sequence variants in exon 2
E148Q in exon 2 is one of the most frequent sequence altera-
tions in the MEFV gene21 38 either as the sole identiﬁed variant
or in association with known mutated alleles. E148Q is fre-
quently encountered in the general population (up to 30% in
the Asian population according to the Ensembl database39), but
its pathogenic role remains uncertain. A case-control study per-
formed in 2000 analysed the role of E148Q as either a disease-
causing mutation or a sequence variant with no functional
effect. The authors found a similar E148Q mutation frequency
between patients and healthy controls and between patients and
their asymptomatic relatives, the same frequency of M694V/
E148Q genotype among patients with and without FMF and
four patients homozygous for E148Q without any FMF symp-
toms. They concluded that E148Q is a benign alteration and
that in both heterozygous and homozygous patients E148Q
appeared as a non-disease causing variant.21 Nonetheless, the
authors could not exclude a possible pathogenic role in hetero-
zygous patients when E148Q is associated with variants with a
high functional effect (ie, M694V), thus acquiring an effect of
potentiation in compound heterozygous patients or in complex
alleles.21 40
This conclusion was contradicted by Tchernitchko et al who
analysed 233 patients and 213 controls among Sephardic Jews.
They found that E148Q allele frequency, even when associated
with M694V, is comparable among patients and asymptomatic
relatives and concluded that E148Q can be considered a benign
polymorphism.22
However, even though other authors later conﬁrmed these
data19 showing that E148Q is the most frequent variant in the
healthy population, the pathogenic role of E148Q remains
debateable as demonstrated by the association with other
rheumatic diseases17 or by its role in symptomatic heterozygous
patients when the second allele was not known.15 In conclusion,
the E148Q variant is common, of unknown pathogenic signiﬁ-
cance and as the only MEFV variant does not support the diag-
nosis of FMF (Strength B).
Correlation age at onset: speciﬁc sequence variants
Non-comparative, descriptive studies show a correlation
between speciﬁc sequence variants and an earlier disease onset.
In particular, Padeh et al observed a younger age at onset in
children carrying two mutations (6±4.4 years with two muta-
tions vs 10±6.4 years in those with no mutations), especially if
homozygous for M694V (4±0.7 years for M694V/M694V vs
7.6±4.4 for M694V/V726A; 10.8±5.1 years for M694V/
E148Q and 9.5±5.2 years for V726A/V726A).26 Ozturk and
coworkers conﬁrmed these results showing that patients with
two mutated alleles have a lower age at disease onset than
patients with one mutated allele.15 Dewalle et al observed a
mean age of 6.4±5 years in patients homozygous for M694V
compared with 13.6±8.9 years in non-homozygous patients.
More than half of homozygous M694V patients manifested the
disease before the age of 5 years.24 We can conclude that
patients homozygous for M694V mutation are at risk for early
onset disease (Strength C).
Silent carriers and risk of AA amyloidosis
AA amyloidosis is the most severe complication of FMF. The
underlying mechanisms are unclear but recent genetic advances
have begun elucidating some of them. M694V appears to be a
risk factor for FMF complications and is the most frequently
associated mutation with amyloidosis (see paragraph ‘Genotype-
phenotype correlation’ above). Many studies have focused on
the importance of genetics in amyloidosis,41–43 but additional
non-genetic factors such as environment are also relevant. In
1974, a study showed that no cases of amyloidosis were found
among 100 Armenian FMF patients living in the USA, although
M694V was demonstrated to be the most frequent MEFV muta-
tion.44 The relevance of the country of residence in determining
risk of AA amyloidosis was analysed by Touitou et al in 2482
patient from 14 countries, with renal outcome data available for
2277 patients; amyloidosis was found in 260/2277. They found
that the country of recruitment, which is roughly the same as
the country of residence, was the most important determinant
of risk for the development of amyloidosis. Homozygosity for
M694V was the second most important risk factor in
Armenians, Israelis and Arabians, but its association with AA
amyloidosis was less signiﬁcant in Turkish patients and undetect-
able among other ethnicities. The ﬁndings suggest that the risk
of AA amyloidosis in patients with M694V depends on the
country of recruitment. This is very important as it affects risk–
beneﬁt considerations on using colchicine prophylaxis in asymp-
tomatic individuals incidentally discovered to be homozygous
for M694V. The authors suggest a more conservative approach,
such as monitoring by urinalysis every 6 months, might be
appropriate in areas such as Western Europe with low risk of
renal amyloidosis.28
Different conclusions were reached by studies focusing on
genetics as the main risk factor for amyloidosis.16 19 25 26
A meta-analysis of 3505 Turkish patients showed that 189/400
affected by amyloidosis were homozygous for M694V. The
authors concluded that asymptomatic or mildly symptomatic
patients homozygous for M694V should receive treatment even
in countries where amyloidosis is rarely encountered.27
In conclusion, the literature reports that both genetic and
environmental factors play a decisive role in disease pathogen-
esis.45 Accordingly, subjects homozygous for M694V who do
not report symptoms, should be evaluated and followed closely
in order to consider therapy (Strength A). For individuals with
two pathogenic mutations for FMF who do not report symp-
toms, if there are risk factors for AA amyloidosis (such as the
country, family history and persistently elevated inﬂammatory
markers, particularly serum amyloid A protein), close follow-up
should be started and treatment considered (Strength B).
Role of the specialist in FMF diagnosis
The primary importance of a clinical diagnosis, even as genetic
testing becomes more generally affordable, together with the
often difﬁcult interpretation of MEFV gene mutations, raises the
issue of the role of the specialist in selecting when genetic
testing will aid management. In the ﬁrst years of genetics for
FMF, the diagnostic problem was thought to be solved simply
by asking for genetic screening. Then, it became clear that many
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patients with FMF might have atypical presentations, with difﬁ-
culties in understanding the indication for genetic testing, or
might be asymptomatic despite carrying sequence variants,
raising doubts about prophylaxis and treatment. Among the
selected papers, one descriptive study on 446 patients analysed
for MEFV mutations showed that only 43% of the patients
referred by a general practitioner were genetically conﬁrmed
versus 76.4% of patients referred by an FMF specialist.23
Therefore, a consultation with an autoinﬂammatory specialist
may aid in the indication and interpretation of genetic testing
and the diagnosis (Strength C).
CONCLUSIONS
The ability to diagnose FMF has improved in recent years,
resulting in earlier initiation of treatment for many patients.
The role of genetics in supporting the diagnosis is crucial, but it
should never be substituted for a clinical diagnosis. Based on
this understanding, the specialist must be aware of the indica-
tions and limitations of genetic testing, and know how to inter-
pret the results. Additional training in this area is suggested,
especially in the era of increased genetic testing in many coun-
tries. The need for consensus guidelines for interpretation of
genetic testing in AID resulted in the recommendations by
Shinar et al in 2012. The authors proposed interpreting genetic
testing according to classiﬁcation of gene variants. The value of
this was conﬁrmed in a consensus meeting.46 Our diagnostic
recommendations (table 3), together with the indications given
by Shinar et al, propose a diagnostic algorithm for FMF that
can help the inexperienced physician.
Author afﬁliations
1Department of Pediatric Immunology, UMC, Utrecht, The Netherlands
2Laboratory for Translational Immunology, UMC, Utrecht, The Netherlands
3NIH, Bethesda, USA
4Reference Centre for Autoinﬂammatory Disorders (CEREMAI) Centre Hospitalier de
Versailles, Le Chesnay Cedex, France
5Charite University Medicine, Berlin, Germany
6Cerrahpasa Ic Hastaliklari Klinigi, Istanbul, Turkey
7Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
8Infection, Inﬂammation and Rheumatology Section, UCL Institute of Child Health,
London, UK
9Policlinico Le Scotte, University of Siena, Siena, Italy
10Department of Pediatrics, UMC, Utrecht, The Netherlands
11Reference Centre for Autoinﬂammatory Disorders CEREMAI, Bicêtre Hospital,
University of Paris SUD, Le Kremlin Bicêtre Cedex, France
12UO Pediatria II, G. Gaslini Institute, Genova, Italy
13Centre national de référence des amyloses d’origine inﬂammatoire et de la ﬁèvre,
Hôpital Tenon, AP-HP, Université Pierre-et-Marie-Curie, Paris, France
14Pediatric Rheumatology, Department of Pediatrics, University of Lausanne,
Lausanne and University of Geneva, Geneva, Switzerland
15Division of Paediatric Rheumatology, Reference Centre for Autoinﬂammatory
Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France
16Klinik für Kinder- und Jugendmedizin, Abteilung für pädiatrische Rheumatologie,
Autoinﬂammation Reference Center Tübingen, Universitätsklinikum Tübingen,
Tübingen, Germany
17National Amyloidosis Centre, University College London Medical School, London,
UK
18Department of Medicine, Division of General Internal Medicine, Radboud
University Nijmegen Medical Center, Nijmegen, The Netherlands
19Gulhane Military Medical Faculty, Institute of Health Sciences, R&D Center,
Ankara, Turkey
20University of Toronto, The Hospital for Sick Children, Toronto, Canada
21Department of Pediatrics, Meir Medical Center, Kfar Saba, Tel Aviv University,
Sackler School of Medicine, Tel Aviv, Israel
22Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
Acknowledgements International Society for Autoinﬂammatory Diseases (ISSAID)
endorsed these recommendations. The initial ﬁndings of the project were presented
at 2014 ACR/ARHP Annual Meeting. We thank Faye Schreiber for medical editing.
Funding This project is supported by a grant from European Agency for Health and
Consumers (EAHC), grant number 2011 1202. The initial ﬁndings of the project
were presented at 2014 ACR/ARHP Annual Meeting. We thank Faye Schreiber for
medical editing.
Contributors GG and NMTH contributed equally to this work as ﬁrst authors; SO
and YU contributed equally as senior authors.
Competing interests NW Grant/Research Support from Abbvie, GSK, Roche,
Consultant for Genzyme, Novartis, Pﬁzer, Roche; S J Vastert Consultant for Novartis; VH
Consultant for Novartis; TK Grant/Research Support from Novartis, Speaker Bureau of
Novartis, SOBI; JA Grant/Research Support from Abbvie, Novartis, Pﬁzer, Consultant for
Novartis, Speaker Bureau of Abbvie, Novartis, Pﬁzer, Roche, SOBI; PB Grant/Research
Support from Novartis, Roche, Consultant for Roche and SOBI; LC Grant/Research
Support from Novartis, SOBI, Consultant for Novartis, SOBI; JF Grant/Research Support
from Takeda, Consultant for Novartis, Speaker Bureau of SOBI; CG Grant/Research
Support from Novartis; MG Grant/Research Support and speaker Bureau from Novartis
and SOBI; GG Consultant for Novartis; MH Consultant for Novartis;; IK-P Grant/
Research Support from Chugai, Novartis, SOBI, Consultant for Abbvie, Chugai, Novartis,
Pﬁzer, SOBI, Speaker Bureau of Novartis, Pﬁzer; JK-D Grant/Research Support from
Novartis, Speaker Bureau of SOBI; HJL Research Support and speaker Bureau from
Novartis; AS Consultant for Novartis, Xoma, SOBI; YU Grant/Research Support from
Novartis, Consultant for Novartis, Speaker Bureau of Abbvie, Neopharm, Novartis,
Roche; SO Consultant for Novartis, Speaker Bureau of Biovitrium.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement We think that, by having used the EULAR standardised
operating procedures for developing diagnostic and therapeutic guidelines and by
the support and collaboration of many international experts in this disease, our
submitted paper really adds to the current literature in the ﬁeld of genetics in
familial Mediterranean fever.
Correction notice This article has been corrected since it was published Online
First. The Funding and Acknowledgements statements have been revised.
REFERENCES
1 Aksentijevich I, Kastner DL. Genetics of monogenic autoinﬂammatory diseases: past
successes, future challenges. Nat Rev Rheumatol 2011;7:469–78.
Table 3 Recommendations for familial Mediterranean fever (FMF) genetic diagnosis
Strength of
evidence
1. FMF is a clinical diagnosis, which can be supported but not excluded by genetic testing B
2. Consider patients homozygous for M694V at risk of developing, with very high probability, a severe phenotype B
3. FMF patients carrying two of the common mutated alleles (homozygotes or compound heterozygotes), especially for M694V mutation or mutations at
position 680 to 694 on exon 10, must be considered at risk of having a more severe disease
B
4. The E148Q variant is common, of unknown pathogenic significance and, as the only MEFV variant, does not support the diagnosis of FMF B
5. Patients homozygous for M694V mutation are at risk of early onset disease C
6. Individuals homozygous for M694V who are not reporting symptoms should be evaluated and followed closely in order to consider therapy A
7. For individuals with two pathogenic mutations for FMF who do not report symptoms, if there are risk factors for AA amyloidosis (such as the country,
family history and persistently elevated inflammatory markers, particularly serum amyloid A protein), close follow-up should be started and treatment
considered
B
8. Consultation with an autoinflammatory disease specialist may be helpful in order to aid in the indication and interpretation of the genetic testing and
diagnosis
C
640 Giancane G, et al. Ann Rheum Dis 2015;74:635–641. doi:10.1136/annrheumdis-2014-206844
Recommendation
group.bmj.com on January 25, 2017 - Published by http://ard.bmj.com/Downloaded from 
2 Ozen S, Bilginer Y. A clinical guide to autoinﬂammatory diseases: familial
Mediterranean Fever and next-of-kin. Nat Rev Rheumatol 2014;10:135–47.
3 Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the world. Arthritis Rheum
2009;61:1447–53.
4 Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the
practical management of Familial Mediterranean Fever. Semin Arthritis Rheum
2013;43:387–91.
5 Padeh S, Livneh A, Pras E, et al. Familial Mediterranean Fever in the ﬁrst two years
of life: a unique phenotype of disease in evolution. J Pediatr 2010;156:985–9.
6 Deng Z, Sood R, Balow JE, et al. Ancient missense mutations in a new member of
the RoRet gene family are likely to cause. Cell 1997;90:797–807.
7 The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat
Genet 1997;17:25–31.
8 Stoffels M, Szperl A, Simon A, et al. MEFV mutations affecting pyrin amino acid
577 cause autosomal dominant autoinﬂammatory disease. Ann Rheum Dis
2014;73:455–61.
9 Sarrauste de Menthiere C. INFEVERS: the Registry for FMF and hereditary
inﬂammatory disorders mutations. Nucleic Acids Res 2003;31:282–5.
10 Federici S, Calcagno G, Finetti M, et al. Clinical impact of MEFV mutations in
children with periodic fever in a prevalent western European Caucasian population.
Ann Rheum Dis 2012;71:1961–5.
11 Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating
procedures for the elaboration, evaluation, dissemination, and implementation of
recommendations endorsed by the EULAR standing committees. Ann Rheum Dis
2004;63:1172–6.
12 Whiting P, Dinnes J, Kleijnen J. Methods for assessing the quality of diagnostic
accuracy studies. Health Technol Assess (Rockv) 2004;8:1–234.
13 Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for
gout. Part I: diagnosis. Report of a task force of the Standing Committee for
International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis
2006;65:1301–11.
14 Delbecq AL. A group process model for problem identiﬁcation and program
planning. J Appl Behav Sci 1971;7:466–92.
15 Ozturk C, Halicioglu O, Coker I, et al. Association of clinical and genetical features
in FMF with focus on MEFV strip assay sensitivity in 452 children from western
Anatolia, Turkey. Clin Rheumatol 2012;31:493–501.
16 Grateau G, Pêcheux C, Cazeneuve C, et al. Clinical versus genetic diagnosis of
familial Mediterranean fever. QJM 2000;93:223–9.
17 Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean
fever: do they predispose to inﬂammation? J Rheumatol 2003;30:2014–18.
18 Migita K, Ida H, Moriuchi H, et al. Clinical relevance of MEFV gene mutations in
Japanese. J Rheumatol 2012;39:875–7.
19 Mattit H, Joma M, Al-Cheikh S, et al. Familial Mediterranean fever in the Syrian
population: gene mutation frequencies, carrier rates and phenotype-genotype
correlation. Eur J Med Genet 2006;49:481–6.
20 Giaglis S, Papadopoulos V, Kambas K, et al. MEFV alterations and population
genetics analysis in a large cohort of Greek patients with familial Mediterranean
fever. Clin Genet 2007;71:458–67.
21 Ben-Chetrit E, Lerer I, Malamud E, et al. The E148Q mutation in the MEFV gene: is
it a disease-causing mutation or a sequence variant? Hum Mutat 2000;15:385–6.
22 Tchernitchko D, Legendre M, Cazeneuve C, et al. The E148Q MEFV allele is not
implicated in the development of familial Mediterranean fever. Hum Mutat
2003;22:339–40.
23 Ben-Chetrit E, Urieli-Shoval S, Calko S, et al. Molecular diagnosis of FMF: lessons
from a study of 446 unrelated individuals. Clin Exp Rheumatol 2002;20:S25–9.
24 Dewalle M, Domingo C, Rozenbaum M, et al. Phenotype-genotype correlation in
Jewish patients suffering from familial Mediterranean fever (FMF). Eur J Hum Genet
1998;6:95–7.
25 Camus D, Shinar Y, Aamar S, et al. “Silent” carriage of two familial Mediterranean
fever gene mutations in large families with only a single identiﬁed patient. Clin
Genet 2012;82:288–91.
26 Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in
216 Israeli children with Familial Mediterranean fever. J Rheumatol
2003;30:185–90.
27 Akpolat T, Özkaya O, Özen S. Homozygous M694V as a risk factor for amyloidosis
in Turkish FMF patients. Gene 2012;492:285–9.
28 Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for
renal amyloidosis in familial Mediterranean fever. Arthritis Rheum
2007;56:1706–12.
29 Settin A, El-Baz R, Abd Rasool M, et al. Clinical and molecular diagnosis of Familial
Mediterranean Fever in Egyptian children. J Gastrointestin Liver Dis 2007;16:141–5.
30 Samli H, Dogru O, Bukulmez A, et al. Mediterranean fever gene mutations in a
cohort. Saudi Med J 2006;90:1822–6.
31 Tchernitchko D, Moutereau S, Legendre M, et al. MEFV analysis is of particularly
weak diagnostic value for recurrent fevers in Western European Caucasian patients.
Arthritis Rheum 2005;52:3603–5.
32 Sohar E, Gafni J, Pras M, et al. Familial Mediterranean Fever. A survey of 470 cases
and review of the literature. Am J Med 1967;43:227–53.
33 Sohar Ezra, Gafni Joseph PM. Tel Hashomer criteria for the diagnosis of FMF. First
International Conference on FMF. London and Tel Aviv: Freund Publishing House,
1997:207.
34 Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial
Mediterranean fever. Arthritis Rheum 1997;40:1879–85.
35 Yalçinkaya F, Ozen S, Ozçakar ZB, et al. A new set of criteria for the diagnosis of
familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009;48:395–8.
36 Kondi A, Hentgen V, Piram M, et al. Validation of the new paediatric criteria for the
diagnosis of familial Mediterranean fever: data from a mixed population of 100
children from the French reference centre for auto-inﬂammatory disorders.
Rheumatology (Oxford) 2010;49:2200–3.
37 Pras E, Livneh A, Balow JE, et al. Clinical differences between North African and
Iraqi Jews with familial Mediterranean fever. Am J Med Genet 1998;75:216–19.
38 Aksentijevich I, Torosyan Y, Samuels J, et al. Mutation and haplotype studies of
familial Mediterranean fever reveal new ancestral relationships and evidence for a
high carrier frequency with reduced penetrance in the Ashkenazi Jewish population.




40 Gershoni-Baruch R, Brik R, Shinawi M, et al. The differential contribution of MEFV
mutant alleles to the clinical proﬁle of familial Mediterranean fever. Eur J Hum
Genet 2002;10:145–9.
41 Cazeneuve C, Sarkisian T, Pêcheux C, et al. MEFV-Gene analysis in armenian
patients with Familial Mediterranean fever: diagnostic value and unfavorable renal
prognosis of the M694V homozygous genotype-genetic and therapeutic
implications. Am J Hum Genet 1999;65:88–97.
42 Gershoni-Baruch R, Shinawi M, Leah K, et al. Familial Mediterranean fever:
prevalence, penetrance and genetic drift. Eur J Hum Genet 2001;9:634–7.
43 Tunca M, Akar S, Onen F, et al. Familial Mediterranean Fever (FMF) in Turkey:
results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1–11.
44 Schwabe AD, Peters RS. Familial Mediterranean fever in Armenians: analysis of 100
cases. Medicine (Baltimore) 1974;53:453–62.
45 Ozen S, Demirkaya E, Amaryan G, et al. Results from a multicentre international
registry of familial Mediterranean fever: impact of environment on the expression of
a monogenic disease in children. Ann Rheum Dis 2014;73:662–7.
46 Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of
hereditary recurrent fevers. Ann Rheum Dis 2012;71:1599–605.
Giancane G, et al. Ann Rheum Dis 2015;74:635–641. doi:10.1136/annrheumdis-2014-206844 641
Recommendation
group.bmj.com on January 25, 2017 - Published by http://ard.bmj.com/Downloaded from 
fever
genetic diagnosis of familial Mediterranean 
Evidence-based recommendations for
Simon, Erkan Demirkaya, Brian Feldman, Yosef Uziel and Seza Ozen
Kone-Paut, Jasmin Kuemmerle-Deschner, Helen J Lachmann, Anna 
IsabelleCaroline Galeotti, Marco Gattorno, Gilles Grateau, Michael Hofer, 
Ozdogan, Jordi Anton, Paul Brogan, Luca Cantarini, Joost Frenkel,
Vastert, Karyl Barron, Veronique Hentgen, Tilmann Kallinich, Huri 
Gabriella Giancane, Nienke M Ter Haar, Nico Wulffraat, Sebastiaan J
doi: 10.1136/annrheumdis-2014-206844
2015
2015 74: 635-641 originally published online January 27,Ann Rheum Dis 
 http://ard.bmj.com/content/74/4/635






Supplementary material can be found at: 
References
 #BIBLhttp://ard.bmj.com/content/74/4/635
This article cites 44 articles, 13 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections




 (4253)Connective tissue disease
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 25, 2017 - Published by http://ard.bmj.com/Downloaded from 
